AbbVie Inc (ABBV)
Official siteHEALTHCARE • DRUG MANUFACTURERS - GENERAL • NYSE
Market Cap: $521.50B
Last updated: Nov 17, 2026 at 4:41 PM ET
AbbVie Inc (ABBV) Statistics
AbbVie (ABBV) has a market cap of $521.50B and an enterprise value of $591.63B. Its trailing P/E of 22.8x is above its 10-year median of 12.5x.
Total Valuation
Enterprise value is 13.45% above the market cap, as debt exceeds cash.
| Market Cap | $521.50B |
|---|---|
| Enterprise Value | $591.63B |
| Latest price (Nov 17, 2026) | $292.91 |
Key Dates
The next earnings report is expected on Feb 2, 2027, covering the quarter ending Dec 31, 2026. The next ex-dividend date is Jan 15, 2027.
| Next Earnings Date | Feb 2, 2027 (expected) |
|---|---|
| Last Earnings Date | Oct 30, 2026 |
| Next Ex-Dividend Date | Jan 15, 2027 |
| Next Payment Date | Feb 16, 2027 |
| Fiscal Year End | December |
Valuation Ratios
The price to sales ratio is 7.8x. Its year-end P/E ranged from 9.9x to 22.8x from 2016 to 2025.
| P/E Ratio | 22.8x |
|---|---|
| Forward P/E | 20.5x |
| P/S Ratio | 7.8x |
| Forward P/S | 7.7x |
| P/FCF Ratio | 27.5x |
| P/OCF Ratio | 26.0x |
| PEG Ratio | 1.4 |
Enterprise Valuation
Counting debt and cash, the company is valued at 25.4x EBITDA and 31.2x free cash flow.
| EV / Earnings | 57.2x |
|---|---|
| EV / Sales | 9.0x |
| EV / EBITDA | 25.4x |
| EV / EBIT | 38.2x |
| EV / FCF | 31.2x |
Price Statistics
The stock is up 29.04% over 52 weeks and trades 6.01% above its 50-day average.
| Beta (1Y) | -0.01 |
|---|---|
| 52-Week Change | +29.04% |
| 1-Month Change | +3.62% |
| 3-Month Change | +10.80% |
| 6-Month Change | +38.00% |
| 5-Year Change | +157.16% |
| 10-Year Change | +428.67% |
| Total Return (1Y) | +32.09% |
| Total Return (3Y CAGR) | +32.52% |
| Total Return (5Y CAGR) | +24.37% |
| Return vs SPY (1Y) | +16.65% |
| Max Drawdown (1Y) | -15.74% |
| Max Drawdown (3Y) | -20.73% |
| Sharpe Ratio (1Y) | 0.99 |
| Correlation with SPY (1Y) | -0.01 |
| 50-Day Average | $276.31 |
| 200-Day Average | $239.43 |
| 52-Week Range | $188.25 to $302.93 |
| RSI (14 Days) | 59.2 |
| Average Volume (20 Days) | 5.15M |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 0.87x current liabilities.
| Current Ratio | 0.87x |
|---|---|
| Quick Ratio | 0.75x |
| Debt / EBITDA | 3.49x |
| Debt / FCF | 4.29x |
Returns and Efficiency
Return on invested capital is 16.39% over the last 12 months, against a 5-year average of 11.67%.
| Return on Assets (ROA) | 7.01% |
|---|---|
| Return on Invested Capital (ROIC) | 16.39% |
| Return on Capital Employed (ROCE) | 14.81% |
| ROA (5Y Average) | 5.27% |
| ROIC (5Y Average) | 11.67% |
| Asset Turnover | 0.47x |
| Inventory Turnover | 3.97x |
| Receivables Turnover | 4.83x |
| Cash Conversion Cycle | -430 days |
Taxes
Income tax took 19.24% of pretax income over the last 12 months.
| Income Tax (TTM) | $2.47B |
|---|---|
| Effective Tax Rate | 19.24% |
Scores
ABBV has an Altman Z-Score of 2.64, in the grey zone from 1.81 to 2.99, and a Piotroski F-Score of 7 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 2.64 |
|---|---|
| Altman Z Zone | Grey |
| Piotroski F-Score | 7 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $66.01B over the last 12 months is up 10.68% from the 12 months before.
| Revenue | $66.01B |
|---|---|
| Revenue Growth (YoY) | +10.68% |
| Gross Profit | $45.33B |
| Operating Income | $21.23B |
| Pretax Income | $12.81B |
| Net Income | $10.35B |
| EBITDA | $23.16B |
| EBIT | $15.49B |
| Reported EPS (TTM) | $12.83 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
| Cash and Equivalents | $10.77B |
|---|---|
| Total Debt | $80.90B |
| Net Debt | $70.13B |
| Net Debt Per Share | $39.64 |
| Working Capital | -$5.62B |
| Shareholder Equity | -$4.58B |
| Tangible Book Value | -$99.03B |
| Total Assets | $147.68B |
| Total Liabilities | $152.22B |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $1.22B of capital spending, operating cash flow left $18.87B of free cash flow.
| Operating Cash Flow | $20.09B |
|---|---|
| Capital Expenditures | $1.22B |
| Free Cash Flow | $18.87B |
| FCF Per Share | $10.68 |
| Depreciation and Amortization | $7.67B |
| Dividends Paid | $12.14B |
| Share Repurchases | $1.53B |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is 32.16%, against a 5-year average of 25.49%.
| Gross Margin | 68.67% |
|---|---|
| Operating Margin | 32.16% |
| Pretax Margin | 19.41% |
| Net Margin | 15.68% |
| EBITDA Margin | 35.08% |
| EBIT Margin | 23.47% |
| FCF Margin | 28.59% |
| Gross Margin (5Y Average) | 66.44% |
| Operating Margin (5Y Average) | 25.49% |
| Net Margin (5Y Average) | 12.89% |
Growth
Revenue grew 1.75% a year over 3 years, and EPS fell 10.16% a year.
| Revenue Growth (3Y CAGR) | +1.75% |
|---|---|
| Revenue Growth (5Y CAGR) | +5.95% |
| EPS Growth (3Y CAGR) | -10.16% |
| EPS Growth (5Y CAGR) | -0.99% |
| FCF Growth (3Y CAGR) | -9.76% |
| FCF Growth (5Y CAGR) | +1.19% |
| Operating Income Growth (3Y CAGR) | -5.94% |
Dividends and Yields
ABBV pays out 60.94% of earnings as dividends.
| Dividend Per Share (Annual) | $6.92 |
|---|---|
| Dividend Yield | 2.36% |
| Payment Schedule | Quarterly |
| Dividend Growth (3Y CAGR) | +5.17% |
| Dividend Growth (5Y CAGR) | +6.81% |
| Payout Ratio | 60.94% |
| FCF Payout Ratio | 64.32% |
| Earnings Yield | 4.39% |
| FCF Yield | 3.64% |
| Buyback Yield | 0.30% |
| Shareholder Yield | 2.64% |
Peer Position
Against 9 similar companies, ABBV has the 4th highest P/E.
P/E RatioPeer median 19.8x
P/S RatioPeer median 4.9x
ROICPeer median 13.16%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +7.17%
Dividend YieldPeer median 2.39%
| P/E Ratio | 22.8x vs 19.8x median |
|---|---|
| P/S Ratio | 7.8x vs 4.9x median |
| ROIC | 16.39% vs 13.16% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +10.68% vs +7.17% median |
| Dividend Yield | 2.36% vs 2.39% median |
Analyst Forecast
Consensus estimates put revenue growth at 9.96% and EPS growth at 27.26% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +9.96% |
|---|---|
| EPS Growth Forecast (2Y CAGR) | +27.26% |
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Overvalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About ABBV
What is ABBV's market cap?
AbbVie has a market cap of $521.50B. Its enterprise value, which adds debt and subtracts cash, is $591.63B.
What is ABBV's P/E ratio?
AbbVie has a trailing P/E ratio of 22.8x and a forward P/E of 20.5x.
How many shares of ABBV are outstanding?
AbbVie has 1.77B shares outstanding. The count is up 0.00% from a year earlier.
Does ABBV pay a dividend?
Yes. AbbVie pays $6.92 a share a year, a dividend yield of 2.36%.
How much debt does ABBV have?
AbbVie has $80.90B of total debt and $10.77B of cash and equivalents, a net debt position of $70.13B.
ABBV pages: Overview, Dividends, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors, Government Contracts